BIVV001

01/01/2020 - "BIVV001 is the first rFVIII with the potential to significantly change the treatment paradigm for severe hemophilia A by providing optimal protection against all bleed types, with less frequent doses. "
01/01/2021 - "BIVV001 is a bioengineered clinical-stage FVIII molecule for the treatment of hemophilia A. "
10/01/2020 - "BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A."
10/01/2020 - "In a small, early-phase study involving men with severe hemophilia A, a single intravenous injection of BIVV001 resulted in high sustained factor VIII activity levels, with a half-life that was up to four times the half-life associated with recombinant factor VIII, an increase that could signal a new class of factor VIII replacement therapy with a weekly treatment interval. "
01/01/2020 - "BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice."

10/01/2020 - "No inhibitors to factor VIII were detected and no hypersensitivity or anaphylaxis events were reported up to 28 days after the injection of single-dose BIVV001. "

10/01/2020 - "No inhibitors to factor VIII were detected and no hypersensitivity or anaphylaxis events were reported up to 28 days after the injection of single-dose BIVV001. "